SO
VTGN icon

STRS Ohio’s VistaGen Therapeutics VTGN Stock Holding History

STRS Ohio’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,477
Closed -$139K – 2329
2021
Q2 		$139K Buy
+1,477
New +$109K ﹤0.01% 1906

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

STRS Ohio's VTGN Position: Q3 2021 in Review

STRS Ohio sold out of VistaGen Therapeutics (VTGN) in Q3 2021, closing a stake of 1,477 shares — an estimated $139K sold.

STRS Ohio first reported a position in VTGN in Q2 2021 and held it in 1 quarter. The position peaked at $139K in Q2 2021. 104 funds tracked by Wall St. Rank hold VTGN as of Q3 2021.

  • STRS Ohio reported no remaining VistaGen Therapeutics position as of Q3 2021 after selling out during the quarter.
  • STRS Ohio sold 1,477 VistaGen Therapeutics shares in Q3 2021, an estimated $139K.
  • STRS Ohio first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 1 quarter.
  • STRS Ohio's VistaGen Therapeutics position peaked at $139K in Q2 2021.
  • 104 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2021.

Based on STRS Ohio's 13F filing for Q3 2021, filed 22 Oct 2021.